FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of cancer and worldwide for other acute health conditions, has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its Sonatherm 600i High Intensity Focused Ultrasound (“HIFU”) Soft Tissue Ablation System in the United States, which will be used to ablate certain soft tissue lesions, excluding the prostate gland, in general surgery.
